Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
2020 Recap by Pantelis Vlachos, Principal/Strategic Consultant, Cytel
Bayesian Methods for Multiple Cohort Expansion (MuCE) designs
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice